澳门金莎网站,澳门金莎娱乐手机版

中文ENGLISH
分享到 

About Haisco

HOME > About haisco > subsidiary profile

澳门金莎网站

澳门金莎网站

Subsidiary introduction

Liaoning Haisco Pharmaceutical Co., Ltd.

Established on May 19, 2005 with a registered capital of 780 million yuan, Liaoning Haisco Pharmaceutical Co., Ltd. was approved as a national-level high-tech enterprise in July 2011. With a land area of approximately 77,000 square meters, and more than 50,000 square meters of all kinds of plants and supporting facilities in compliance with GMP requirements of China, the company has 12 professional production lines for the production of small-volume injections (including prefilled syringes), freeze-dried powder injections (including hormones), powder injections (cephalosporins), large-volume injections (including multi-layer co-extruded infusion bags), active pharmaceutical ingredient (API), etc. The multi-chamber bag production line geared to international top standards has been completed, and the company is the first one (and currently the only one) in China that has obtained the production license in this field. The products have been launched at the end of 2015, filling the gap in multi-chamber bag production in China.

Great importance has already been attached to the development of new products. The launched products cover a number of therapeutic fields, including anti-infective, digestive system, blood system, nervous system and parenteral nutrition. As of July 2019, Liaoning Haisco has achieved 36 drug production license numbers covering 25 varieties, including compound vitamin for injection (3), medium/long chain fat emulsion injection (C8~24), compound amino acid injection (18AA-VII), dolasetron mesylate injection, fat emulsion amino acid (17) glucose (11%) injection and palonosetron hydrochloride injection. We also own five new drug certificates: namefine hydrochloride injection, dolasetron mesylate injection, compound vitamin for injection (3), argiri ine glutamate injection and arginine glutamic acid injection.



Sichuan Haisco Pharmaceutical Co., Ltd.

Sichuan Haisco Pharmaceutical Co., Ltd., established in August 2007 with a registered capital of 1,300 million RMB (~191 million USD), is a wholly-owned subsidiary of Haisco Pharmaceutical Group Co., Ltd.

It is located in Cross-Strait Science and Technology Park Wenjiang District, Chengdu with a land area of 333 arces, The company produces a wide range of drug products, covering from the fields of cardiovascular diseases, anti-infection, digestive system diseases and CNS system diseases to diabetes and hepatic diseases. In a total, more than twenty varieties are currently being produced or under application. Sichuan Haisco is committed to providing the latest and best quality drug products for patients in China

Sichuan Haisco now has two production sites, Wenjiang and Meishan. Both mainly engage in the production of solid dosage forms such as tablets, capsules, granules, ointments while Meishan site is also capable of APIs manufacturing. Sichuan Haisco is striving to become a first-class modern pharmaceutical research and production site in China that complies with FDA and cGMP standards.